SimInSitu Advances Patient-Specific TAVI Model for Heart Valve Testing

he SimInSitu project has reached a significant milestone in developing a validated computational platform of the human aorta for testing tissue-engineered heart valves (THVs). The project focuses on enhancing the credibility of patient-specific transcatheter aortic valve implantation (TAVI) models, using the Sapien 3 (S3) Ultra device as a reference for Xeltis’ THVs.

A key deliverable highlights the verification, validation, and uncertainty quantification (VVUQ) of the TAVI model. The study analyzed a dataset of 20 patients, assessing model accuracy against clinical data using finite-element and fluid-solid interaction analyses. Results showed strong agreement for structural parameters, while hemodynamic performance exhibited higher variability. The study identified implantation depth and stent material properties as critical factors influencing structural simulations.

The findings confirm the model’s reliability for biomedical device testing, paving the way for evaluating Xeltis' biodegradable TAVI device. SimInSitu continues to advance patient-specific in-silico modeling, supporting innovation in heart valve technologies